K. Bergström et al., “Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M1 and M2 muscarinic acetylcholine receptors in Alzheimer's disease”, European Journal of Nuclear Medicine, vol. 26, No. 11, pp. 1482-1485, Nov. 1999, XP-002193046. |
S. Oya et al., “Small and neutral TcvO BAT, bisaminoethanethiol (N2S2) complexes for developing new brain imaging agents”, Nuclear Medicine & Biology, vol. 25, pp. 35-140, 1998. |
A. Fischman et al., “Rapid detection of parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters”, SYNAPSE, vol. 29, pp. 128-141, 1998. |
J. Logan et al., “Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects”, Journal of Cerebral Blood Flow and metabolism, vol. 10, pp. 740-747, 1990. |
J. Seibyl et al., “Iodine-123-β-CIT an diodine-123-FPCIT SPECT measurement of dopamine transporter in healthy subjects and parkinson's patients”, The Journal of Nuclear Medicine, vol. 39, No. 9, pp. 1500-1508, Sep. 1998. |
M. Melloul et al., “Double-Phase 99mTc-sestamibi scintimammography and trans-scan in diagnosing breast cancer”, The Journal Of Nuclear Medicine, vol. 40, No. 3, pp. 380, Mar. 1999. |
J.L. Moretti et al., “Comparison of brain SPECT using 99mTc-Bicisate (L,L-ECD) and [123I]IMP in cortical and subcortical strokes”, Journal Of Cerebral Blood Flow And Metabolism, vol. 14 (Suppl. 1), pp. S84-S90, 1994. |
J.M. Links, “Visual interpretation,” Chapter 22 in HN Wagner et al. (Eds.), Principles of Nuclear Medicine, W.B. Saunders Company, 2nd Edition, 1995, pp. 391-392. |
EL Palmer et al. (Eds.), Practical Nuclear Medicine, Chapter 3 “Cardiovascular Imaging,” W.B. Saunders Company, 1992, pp. 71-120. |